LeMaitre Vascular (NASDAQ:LMAT) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $96.01 and traded as high as $97.83. LeMaitre Vascular shares last traded at $92.34, with a volume of 284,066 shares changing hands.

Analyst Upgrades and Downgrades

LMAT has been the topic of several analyst reports. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Wells Fargo & Company lifted their target price on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Finally, Citizens Jmp upped their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Stock Down 0.4%

The company has a market capitalization of $2.10 billion, a PE ratio of 33.93, a P/E/G ratio of 2.57 and a beta of 0.54. The stock’s fifty day moving average is $104.09 and its two-hundred day moving average is $96.01. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. During the same quarter in the previous year, the firm posted $0.48 earnings per share. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, analysts predict that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend was Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio is 36.90%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer directly owned 1,430,019 shares in the company, valued at $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bridget A. Ross sold 5,044 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the transaction, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. The trade was a 56.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 54,453 shares of company stock valued at $5,906,174 over the last ninety days. 7.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of LeMaitre Vascular by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after purchasing an additional 21,946 shares during the period. Conestoga Capital Advisors LLC boosted its holdings in LeMaitre Vascular by 3.6% in the 1st quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock worth $161,224,000 after buying an additional 51,825 shares during the period. First Trust Advisors LP grew its stake in LeMaitre Vascular by 6.2% in the 1st quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock valued at $108,959,000 after buying an additional 57,931 shares in the last quarter. State Street Corp raised its holdings in LeMaitre Vascular by 0.8% during the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after acquiring an additional 6,130 shares during the period. Finally, Congress Asset Management Co. raised its holdings in LeMaitre Vascular by 5.8% during the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after acquiring an additional 40,065 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.